Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24?weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Article Dermatology

Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT

Athanasios Tsianakas et al.

Summary: This study demonstrates that TIL is highly effective and safe in real-world settings for patients with moderate-to-severe plaque psoriasis. Patients with scalp and nail involvement or pruritus showed marked improvement.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

添加到收藏夹

Article Dermatology

Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)

Alessandra Narcisi et al.

Summary: This retrospective study assessed the effectiveness and safety of tildrakizumab in the real-life clinical practice for treating plaque psoriasis. The results showed that a significant proportion of patients achieved PASI 75, PASI 90, and PASI 100 at 52 weeks, with higher percentages achieving complete skin clearance. No significant safety concerns were observed, and no patients had to discontinue treatment due to adverse events.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

添加到收藏夹

Article Dermatology

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Angelo Ruggiero et al.

Summary: Background: Tildrakizumab has shown promising efficacy and safety in clinical trials, but real-life data are limited. Objective: To assess the efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis. Results: The study showed significant reduction in PASI score and high rates of PASI90 and PASI100 responses, with few reported adverse events, up to 52 weeks of follow-up. Treatment also improved patients' quality of life.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

添加到收藏夹

Article Dermatology

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

K. B. Gordon et al.

Summary: This study aimed to evaluate residual disease activity during treatment with tildrakizumab. The results showed that PASI scores were more reliable in assessing disease activity compared to percentage PASI improvement, which could partially explain the efficacy disparities between clinical trials and practice. Therefore, supplementing dichotomous PASI improvement with PASI scores and considering patient treatment goals could facilitate clinical decisions.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Elena del Alcazar et al.

Summary: This study aimed to assess the effectiveness and safety of guselkumab in the treatment of moderate to severe plaque psoriasis in routine clinical practice. The results showed that guselkumab had significant efficacy and good safety profile at 24 weeks.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Dermatology

Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients

Katharina A. Drerup et al.

Summary: The study established a prospective cohort to evaluate the efficacy and safety of tildrakizumab in daily practice. Patients in routine practice differed substantially from those in clinical trials, but tildrakizumab showed comparable efficacy and safety in both settings. Prospective cohort studies are a suitable tool to generate real-world evidence before registry data become available.

DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Tildrakizumab: short-term efficacy and safety in real clinical practice

Manuel Galan-Gutierrez et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study

Giacomo Caldarola et al.

Summary: The efficacy and safety of tildrakizumab were evaluated in a real-life setting for patients with moderate-to-severe psoriasis over a 28-week treatment period. The results showed that tildrakizumab had high efficacy and a favorable safety profile, regardless of patient- and disease-related factors.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Letter Dermatology

Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement

Luca Mastorino et al.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Medicine, General & Internal

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

Ricardo Ruiz-Villaverde et al.

Summary: Tildrakizumab has shown excellent results in controlling psoriasis, improving treatment efficacy, safety, and survival rates. Patients with scalp involvement, shorter disease duration, and fewer previous biological therapies have higher survival rates.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal